Colgate's Cost Buffer Is Working; the U.S. Turnaround Still Isn't

Q3 showed broad organic growth and a gross-margin guidance raise, but North America remains a multi-quarter work in process—and pricing is doing more of the heavy lifting.

CL · Earnings Call · 2026-10-30

A good quarter with an old problem

Colgate's Q3 2026 call opened with the familiar claim of solid top- and bottom-line growth. “We are clearly pleased to have delivered another quarter of solid top and bottom line growth, particularly in the context of the continued global volatility we are seeing.” — Noel Wallace, Chairman, President & CEO · 2026-10-30 The quarter had broad organic growth across all four categories and four of five divisions, mid-single-digit emerging-market growth, record European shares, and a strong Hill's. But the central tension is still North America. Noel Wallace described the U.S. reset as “very much a work in process” — Noel Wallace, Chairman, President & CEO · 2026-10-30 and said it is “going to take some time” — Noel Wallace, Chairman, President & CEO · 2026-10-30. That is not a new message. In July he told investors “We recognize that the numbers aren't where they need to be. It won't be a linear improvement” — Noel Wallace, Chairman, President and CEO · 2026-07-31; in January he called it a “Tough quarter for North America” — Noel Wallace, Chairman, President & CEO · 2026-01-30. The cost environment and premium innovation are recurring refrains, not fresh discoveries. The stock reflects that: at $75.96B market cap, CL is still 12.4% below its September 2024 peak, even after a 4.6% bounce in the last 90 trading days.

Pricing is carrying more of the load

The fresher detail is how Colgate is paying for the cost pressure. Pricing contributed 220bp in Q1, 160bp in Q2, and about 200bp in Q3, and management is explicit that pricing has to stay ahead of costs. The company's own keyword set now puts list price near the top of the agenda, which is new language relative to prior calls that talked more broadly about revenue growth management. Wallace framed the toolkit as six or seven levers: “it is price-pack architecture, it is premium line innovation, it is promo optimization” — Noel Wallace, Chairman, President & CEO · 2026-10-30. He also warned pricing will be market-dependent: “In some markets, we will lead with pricing, and others, we will follow.” — Noel Wallace, Chairman, President & CEO · 2026-10-30 The cost math explains why. Stan Sutula said material prices were roughly a 300bp headwind, funding-the-growth productivity offset more than 290bp, pricing added 80bp, and mix added about 20bp.

Material prices were roughly 300 basis points of a headwind in line with our expectations, but it remains a volatile environment around commodities, particularly around oil-based commodities. Helping to offset that was our productivity. So, funding-the-growth drove over 290 basis points of offset to the material inflation.
Stan Sutula, Chief Financial Officer · 2026-10-30

That is a genuinely strong operating result. Colgate raised full-year gross-margin guidance to up from roughly flat, even as cost inflation remains around $300 million and Q4 is guided to be the highest logistics-cost quarter of the year in both dollars and percent of sales. Tariffs are expected to peak in Q4. Unlike several consumer reporters this quarter, Colgate did not lean on tariff refunds: the Q3 benefit was insignificant and none is assumed in Q4. That is a cleaner quality-of-earnings story than a refund-assisted beat.

Hill's and Asia are the proof points; AI is the option

Hill's had a very strong quarter, with organic growth of 6.5% ex-private label, therapeutic and wet/cat leading, and gross margin up 170bp. Prescription diet remains the engine, and the Fresh rollout is deliberately slow. That is good, but it is not new; Hill's has been the consistent bright spot for several quarters. Asia was also strong: India double-digit, Greater China mid-single-digit, Colgate China high-single-digit, and Europe premium brands like elmex taking share. Wallace connected the China playbook to the U.S. reset, saying “there are applications that translate very directly to any market around the world” — Noel Wallace, Chairman, President & CEO · 2026-10-30, especially social commerce and AI-driven content. The AI language is more specific now. PromoAI is scaling in key markets, and Colgate is talking about data personalization and omni-channel demand generation as operating capabilities, not pilots. That aligns with the broader market's obsession with agentic commerce and AI-driven selling, but Colgate is careful not to overclaim: agentic commerce is still emerging and not material. The more important point is that AI is being used to defend advertising ROI while ad spend rises, not to create a new revenue line yet.

The numbers still have a gap

The latest filed quarter, Q2 2026, shows the shape of the problem. Gross margin was 61.5%, up 1.4pp year over year, while operating margin was 19.0%, down 2.2pp and net margin was 13.4%, down 1.7pp. Revenue grew 5% to $5.4B, gross profit rose 7%, but operating income fell 6% and net income fell 7%. That is the tension in one line: the gross-margin engine is working, but advertising, logistics, tariffs, and the U.S. reset are still eating the operating leverage. The stock is not cheap for that mix. It trades at 23.3x operating income, up 36% year over year. Free cash flow is supportive — $829M in Q2, up 11% — and the dividend remains a support, but the valuation leaves little room for another year of U.S. disappointment.

What to watch

The quarter did not change the Colgate story so much as sharpen it. The positive change is that gross-margin guidance went up despite stubborn costs, and management is now talking explicitly about nice growth in emerging markets and premium innovation rather than just defending the base. The unchanged part is North America: the same work-in-process language has now spanned multiple quarters. Q4 will be the test, with peak tariffs and peak logistics costs, and 2027 guidance will be the real referendum on whether pricing and productivity can keep covering the gap. Until U.S. volume and share improve, Colgate looks like a well-run global compounder with a U.S. hole in the middle — not yet a turnaround.